Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Ihle

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Molecular Cancer Therapeutics|May 15, 2023
Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of CancerCatherine Lee, Ziyue Karen Jiang, Simon Planken, et al.
Cancer Research|October 17, 2019
Correction: An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and TumorsMartin Indarte, Roisin Puentes, Marco Maruggi, et al.
Cancer Research|May 2, 2019
An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and TumorsMartin Indarte, Roisin Puentes, Marco Maruggi, et al.
Cell|October 3, 2017
Chemical Proteomics Identifies Druggable Vulnerabilities in a Genetically Defined CancerLiron Bar-Peled, Esther K Kemper, Radu M Suciu, et al.
Journal of the National Cancer Institute|January 17, 2012
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcomeNathan T Ihle, Lauren A Byers, Edward S Kim, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Molecular Cancer Therapeutics|May 15, 2023
Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of CancerCatherine Lee, Ziyue Karen Jiang, Simon Planken, et al.
Cancer Research|October 17, 2019
Correction: An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and TumorsMartin Indarte, Roisin Puentes, Marco Maruggi, et al.
Cancer Research|May 2, 2019
An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and TumorsMartin Indarte, Roisin Puentes, Marco Maruggi, et al.
Cell|October 3, 2017
Chemical Proteomics Identifies Druggable Vulnerabilities in a Genetically Defined CancerLiron Bar-Peled, Esther K Kemper, Radu M Suciu, et al.
Journal of the National Cancer Institute|January 17, 2012
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcomeNathan T Ihle, Lauren A Byers, Edward S Kim, et al.
Pageof 3